Solara Active Pharma - 'Partner Of Choice’ In API, CRAMS Space: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Solara Active Pharma Sciences Ltd. has a differentiated business model, formed by demerging the active pharmaceutical ingredient business of Strides Pharma Ltd. and integrating it with the human API business of Sequent Scientific Ltd.
While young in terms of listing, it has almost three decades of experience, with sales of Rs 16.2 billion/an Ebitda margin of 23.9% over the past 12 months.
The company has built a multi-pronged strategy through;
capacity expansion in core products,
expansion into newer geographies, and
acquiring new customers – to benefit from formulators’ inclination to reduce their dependency on select regions to procure APIs.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.